References

Non-Exhaustive Reference List

  • Aras, O., C. Demirdag, H. Kommidi, H. Guo, I. Pavlova, A. Aygun, E. Karayel, H. Pehlivanoglu, N. Yeyin, N. Kyprianou, N. Chen, S. Harmsen, K. Sonmezoglu, D. J. Lundon, R. Oklu, R. Ting, A. Tewari, O. Akin and H. B. Sayman (2021). "Small Molecule, Multimodal, [18F]-PET and Fluorescence Imaging Agent Targeting Prostate-Specific Membrane Antigen: First-in-Human Study." Clinical genitourinary cancer 19(5): 405-416.
  • Ballal, S., M. P. Yadav, E. S. Moon, V. S. Kramer, F. Roesch, S. Kumari, M. Tripathi, S. T. ArunRaj, S. Sarswat and C. Bal (2021). "Biodistribution, pharmacokinetics, dosimetry of [68Ga]Ga-DOTA.SA.FAPi, and the head-to-head comparison with [18F]F-FDG PET/CT in patients with various cancers." European journal of nuclear medicine and molecular imaging 48(6): 1915-1931.
  • Bauer, M., S. Barna, M. Blaickner, K. Prosenz, K. Bamminger, V. Pichler, N. Tournier, M. Hacker, M. Zeitlinger, G. Karanikas and O. Langer (2021). "Human Biodistribution and Radiation Dosimetry of the P-Glycoprotein Radiotracer [11C]Metoclopramide." Molecular imaging and biology 23(2): 180-185.
  • dos Santos, J. C., M. Schäfer, U. Bauder-Wüst, W. Lehnert, K. Leotta, A. Morgenstern, K. Kopka, U. Haberkorn, W. Mier and C. Kratochwil (2019). "Development and dosimetry of 203Pb/212Pb-labelled PSMA ligands: bringing “the lead” into PSMA-targeted alpha therapy?" European journal of nuclear medicine and molecular imaging 46(5): 1081-1091.
  • Dünger, L., A. Seidlitz, C. Jentsch, I. Platzek, J. Kotzerke, B. Beuthien-Baumann, M. Baumann, M. Krause, E. G. C. Troost and F. Raschke (2021). "Reduced diffusion in white matter after radiotherapy with photons and protons." Radiotherapy and oncology 164: 66-72.
  • Giesel, F. L., S. Adeberg, M. Syed, T. Lindner, L. D. Jiménez-Franco, E. Mavriopoulou, F. Staudinger, E. Tonndorf-Martini, S. Regnery, S. Rieken, R. E. Shafie, M. Röhrich, P. Flechsig, A. Kluge, A. Altmann, J. Debus, U. Haberkorn and C. Kratochwil (2021). "FAPI-74 PET/CT Using Either 18F-AlF or Cold-Kit 68Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients." The Journal of nuclear medicine (1978) 62(2): 201-207.
  • Giesel, F. L., B. Hadaschik, J. Cardinale, J. Radtke, M. Vinsensia, W. Lehnert, C. Kesch, Y. Tolstov, S. Singer, N. Grabe, S. Duensing, M. Schäfer, O. C. Neels, W. Mier, U. Haberkorn, K. Kopka and C. Kratochwil (2017). "F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients." European journal of nuclear medicine and molecular imaging 44(4): 678-688.
  • Grachev, I. D., P. M. Meyer, G. A. Becker, M. Bronzel, D. Marsteller, G. Pastino and O. Voges (2021). "Sigma-1 and dopamine D2/D3 receptor occupancy of pridopidine in healthy volunteers and patients with Huntington disease: a [[.sup.18]F] fluspidine and [[.sup.18]F] fallypride PET study." European journal of nuclear medicine and molecular imaging 48(4): 1103.
  • Hohberg, M., C. Kobe, P. Krapf, P. Täger, J. Hammes, F. Dietlein, B. D. Zlatopolskiy, H. Endepols, M. Wild, S. Neubauer, A. Heidenreich, B. Neumaier, A. Drzezga and M. Dietlein (2019). "Biodistribution and radiation dosimetry of [18F]-JK-PSMA-7 as a novel prostate-specific membrane antigen-specific ligand for PET/CT imaging of prostate cancer." EJNMMI research 9(1): 66-10.
  • Kramer, V., R. Fernandez, W. Lehnert, L. D. Jimenez-Franco, C. Soza-Ried, E. Eppard and M. Ceballos (2021). "Biodistribution and dosimetry of a single dose of albumin-binding ligand [[.sup.177]Lu]Lu-PSMA-ALB-56 in patients with mCRPC." European journal of nuclear medicine and molecular imaging 48(3): 893.
  • Kurkowska, S., B. Birkenfeld and H. Piwowarska-Bilska (2021). "Physical quantities useful for quality control of quantitative SPECT/CT imaging." Nuclear Medicine Review 24(2): 93-98.
  • LEHNERT, W.; SCHMIDT, K.; KIMIAEI, S.; MEYER, T. et al. [P086] Impact of modality (2D planar, 2D/3D hybrid, 3D SPECT) on kidneys absorbed dose in lu-177-based PRRT. Physica medica, 52, p. 125-126, 2018.
  • LEHNERT, W.; RISS, P. J.; HURTADO DE MENDOZA, A.; LOPEZ, S. et al. Whole-body biodistribution and radiation dosimetry of [18F]PR04.MZ: a new PET radiotracer for clinical management of patients with movement disorders. EJNMMI research, 12, n. 1, p. 1-1, 2022.
  • Merkx, R. I. J., D. Lobeek, M. Konijnenberg, L. D. Jiménez-Franco, A. Kluge, E. Oosterwijk and P. F. A. Mulders (2021). "Phase I study to assess safety, biodistribution and radiation dosimetry for 89.sup.Zr-girentuximab in patients with renal cell carcinoma." European journal of nuclear medicine and molecular imaging 48(10): 3277.
  • Mora‐Ramirez, E., L. Santoro, E. Cassol, J. C. Ocampo‐Ramos, N. Clayton, G. Kayal, S. Chouaf, D. Trauchessec, J. P. Pouget, P. O. Kotzki, E. Deshayes and M. Bardiès (2020). "Comparison of commercial dosimetric software platforms in patients treated with 177Lu‐DOTATATE for peptide receptor radionuclide therapy." Medical physics (Lancaster) 47(9): 4602-4615.
  • Nazari, M., A. Kluge, I. Apostolova, S. Klutmann, S. Kimiaei, M. Schroeder and R. Buchert (2022). "Explainable AI to improve acceptance of convolutional neural networks for automatic classification of dopamine transporter SPECT in the diagnosis of clinically uncertain parkinsonian syndromes." European journal of nuclear medicine and molecular imaging 49(4): 1176-1186.
  • Santoro, L., L. Pitalot, D. Trauchessec, E. Mora-Ramirez, P. Kotzki, M. Bardiès and E. Deshayes (2021). "Clinical implementation of PLANET® Dose for dosimetric assessment after [177Lu]Lu-DOTA-TATE: comparison with Dosimetry Toolkit® and OLINDA/EXM® V1.0." EJNMMI Research 11(1): 1.
  • Vergara Gil, A. (2022). Implementation of a clinical dosimetry workflow to perform personalized dosimetry for internal radiotherapy
  • ----IDAC-DOSE-----
  • Mise en œuvre d'un flux de travail de dosimétrie clinique pour réaliser une dosimétrie personnalisée pour la radiothérapie interne vectorisée, Université Paul Sabatier - Toulouse III.
  • ABBASI, A.; DADASHPOUR, M.; ALIPOURFARD, I. Calculation of radium-223 and actinium-225 α-emitter radiopharmaceuticals dose rates in treatment of metastatic castration-resistant prostate cancer. Journal of cancer research and therapeutics, 17, n. 2, p. 348-352, 2021.
  • ABUQBEITAH, M.; DEMIR, M.; SAĞER, S.; ASA, S. et al. SPECT/CT-based dosimetry of salivary glands and iodine-avid lesions following 131I therapy. Health and technology, 13, n. 1, p. 101-110, 2023.
  • ABUQBEITAH, M.; DEMIR, M.; ÇAVDAR, İ.; TANYILDIZI, H. et al. Red bone marrow dose estimation using several internal dosimetry models for prospective dosimetry-oriented radioiodine therapy. Radiation and environmental biophysics, 57, n. 4, p. 395-404, 2018.
  • ANDERSSON, M.; JOHANSSON, L.; ECKERMAN, K.; MATTSSON, S. IDAC-Dose 2.1, an internal dosimetry program for diagnostic nuclear medicine based on the ICRP adult reference voxel phantoms. EJNMMI research, 7, n. 1, p. 88-10, 2017.
  • BALLAL, S.; YADAV, M. P.; MOON, E. S.; KRAMER, V. S. et al. Biodistribution, pharmacokinetics, dosimetry of [68Ga]Ga-DOTA.SA.FAPi, and the head-to-head comparison with [18F]F-FDG PET/CT in patients with various cancers. European journal of nuclear medicine and molecular imaging, 48, n. 6, p. 1915-1931, 2021.
  • CHAUVIN, M.; BORYS, D.; BOTTA, F.; BZOWSKI, P. et al. OpenDose: Open-Access Resource for Nuclear Medicine Dosimetry. Journal of Nuclear Medicine, 61, n. 10, p. 1514-1519, 2020.
  • GRACHEV, I. D.; MEYER, P. M.; BECKER, G. A.; BRONZEL, M. et al. Sigma-1 and dopamine D2/D3 receptor occupancy of pridopidine in healthy volunteers and patients with Huntington disease: a [[.sup.18]F] fluspidine and [[.sup.18]F] fallypride PET study. European journal of nuclear medicine and molecular imaging, 48, n. 4, p. 1103, 2021.
  • KAMP, A.; ANDERSSON, M.; LEIDE-SVEGBORN, S.; NOΒKE, D. et al. A revised compartmental model for biokinetics and dosimetry of 2-[18F]FDG. EJNMMI physics, 10, n. 1, p. 10-10, 2023.
  • KÁLMÁN-SZABÓ, I.; KÉPES, Z.; FEKETE, A.; VÁGNER, A. et al. In Vivo evaluation of newly synthesized 213Bi-conjugated alpha-melanocyte stimulating hormone (α-MSH) peptide analogues in melanocortin-1 receptor (MC1-R) positive experimental melanoma model. Journal of pharmaceutical and biomedical analysis, 229, p. 115374-115374, 2023.
  • MH ZAKALY, H.; Y. A. MOSTAFA, M.; ZHUKOVSKY, M. Labeling of ethylenediamine tetramethylene phosphonate with 153Sm and 177Lu,Comparison Study. Asia-Pacific Journal of Oncology, p. 1-7, 2020
  • MORA‐RAMIREZ, E.; SANTORO, L.; CASSOL, E.; OCAMPO‐RAMOS, J. C. et al. Comparison of commercial dosimetric software platforms in patients treated with 177Lu‐DOTATATE for peptide receptor radionuclide therapy. Medical physics (Lancaster), 47, n. 9, p. 4602-4615, 2020.
  • PETROVA, A. E.; CHIPIGA, L. A.; VODOVATOV, A. V.; STANZHEVSKY, A. A. et al. Estimation of absorbed doses in patients’ organs from the released radionuclide-label during radionuclide therapy with 225Ac. Радиационная гигиена, 15, n. 1, p. 120-131, 2022.
PHONE
+61 (0) 383 766 284
E-MAIL
noreply@envato.com
OIUR ADDRESS

Level 13, 2 Elizabeth St,
Melbourne, Victoria 3000,
Australia

OIUR ADDRESS

Level 13, 2 Elizabeth St,
Melbourne, Victoria 3000,
Australia

Do you have a question?
Feel free to contact

info@quantinm.com

SEND US A MESSAGE
Partners login